Notably, blocking the KRAS mutation–induced m6A increase in the DDB2 and XPC transcripts by METTL3 inhibition substantially sensitizes NSCLC cells to platinum treatment, both in vitro and in vivo. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.